Feasibility and safety of early initiation of a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor in patients with acute myocardial infarction undergoing primary PCI

29 August 2020 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Tomoaki Okada

Kagawa Prefectural Central Hospital, Takamatsu (Japan)

56 More presentations in this session

Presentation thumbnail

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Professor Y. Huo (Beijing, CN)

Abstract Slides

Presentation thumbnail

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

Doctor C. Becker (Wuppertal, DE)

Abstract Slides

Presentation thumbnail

Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics

Doctor S. Frechen (Leverkusen, DE)

Abstract Slides

Presentation thumbnail

Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study

Doctor C. Ballantyne (Houston, US)

Abstract Slides

Presentation thumbnail

The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population

Doctor D. Radenkovic (Greater London, GB)

Abstract Slides

Access the full session

Session thumbnail

Pharmacology and Pharmacotherapy ePosters

The Event

ESC Congress 2020

29 August - 1 September 2020

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

What’s new in LDL lowering?

Congress Presentation

Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources